Earnings guidance

Humana Inc. to Release Second Quarter 2021 Results on July 28, 2021

Retrieved on: 
Thursday, June 24, 2021
Professional services, Health, Hospitals, Insurance, Managed care, General Health, Corporate finance, Humana, New York Stock Exchange, Earnings guidance, Finance, Financial economics, Economy

Humana Inc. (NYSE: HUM) will release its financial results for the second quarter 2021 (2Q21) on Wednesday, July 28, 2021 at 6:30 a.m. Eastern time.

Key Points: 
  • Humana Inc. (NYSE: HUM) will release its financial results for the second quarter 2021 (2Q21) on Wednesday, July 28, 2021 at 6:30 a.m. Eastern time.
  • The company will host a conference call at 9:00 a.m. Eastern time that morning to discuss its financial results for the quarter and earnings guidance for 2021.
  • Humana Inc. (NYSE: HUM) is committed to helping our millions of medical and specialty members achieve their best health.
  • More information regarding Humana is available to investors via the Investor Relations page of the companys website at humana.com , including copies of:

PVH Corp. Updates 2021 Full Year Outlook in Connection With Announcement of the Sale of Its IZOD, Van Heusen, ARROW and Geoffrey Beene Brands to Authentic Brands Group and the Exit From Its Heritage Brands Business

Retrieved on: 
Wednesday, June 23, 2021
Retail, Specialty, Fashion, Corporate finance, Finance, Money, Financial economics, Fundamental analysis, Earnings per share, Earnings guidance

GAAP Basis: The Company now is projecting earnings per share on a GAAP basis for the full year 2021 of approximately $6.60.

Key Points: 
  • GAAP Basis: The Company now is projecting earnings per share on a GAAP basis for the full year 2021 of approximately $6.60.
  • The Companys prior guidance for the full year 2021 earnings per share on a GAAP basis was approximately $5.50.
  • The Companys projected earnings per share on a GAAP basis of $0.79 to $0.82 for the second quarter of 2021 is unchanged.
  • The information presented on a non-GAAP basis may not be comparable to similarly titled measures reported by other companies.

Organon Announces Filing of Form 10-Q for the Quarter Ended March 31, 2021

Retrieved on: 
Monday, June 21, 2021
General Health, Health, Women, Consumer, Corporate finance, SEC filings, New York Stock Exchange, Form 10-Q, Earnings guidance, Finance, Financial economics, Economy, Schering-Plough

Organon (NYSE: OGN) (the company), today announced that it has filed a Form 10-Q for the quarter ended March 31, 2021.

Key Points: 
  • Organon (NYSE: OGN) (the company), today announced that it has filed a Form 10-Q for the quarter ended March 31, 2021.
  • A copy of the Form 10-Q, along with a related Frequently Asked Questions document, and supplemental revenue information, has been posted to the companys website, www.organon.com/investor-relations .
  • The results of the first quarter were incorporated into Organons guidance for full year 2021, which was provided as part of the companys May 3, 2021 virtual Investor Day co-hosted by Merck.
  • Organon plans to release its second quarter results for the quarter and six months ended June 30, 2021 on or about August 12, 2021, and will host its first conference call as a standalone, publicly-traded company on the same day.

Codexis Raises 2021 Guidance Following Receipt of Significant New Order for a Proprietary Enzyme Product

Retrieved on: 
Thursday, June 17, 2021
Codexis, Guidance, Earnings guidance, Companies, Academic disciplines, Technology

The majority of this order was not included in Codexis prior guidance for 2021; accordingly, the Company is raising its 2021 guidance for total revenues to a range of $89 million to $93 million, up from previous guidance of $82 million to $85 million.

Key Points: 
  • The majority of this order was not included in Codexis prior guidance for 2021; accordingly, the Company is raising its 2021 guidance for total revenues to a range of $89 million to $93 million, up from previous guidance of $82 million to $85 million.
  • Codexis is also increasing its 2021 guidance for product revenue to a range of $45 million to $48 million, up from previous guidance of $36 million to $39 million.
  • In addition, the Company is raising 2021 guidance for product gross margin to a range of 60% to 64%, up from previous guidance of 54% to 58%.
  • Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver platform to discover and develop novel, high performance enzymes and novel biotherapeutics.

Cleveland-Cliffs Announces Increase to Second-Quarter and Full-Year 2021 Financial Guidance

Retrieved on: 
Tuesday, June 15, 2021
Engineering, Mining, Minerals, Manufacturing, Natural Resources, Other Manufacturing, Steel, Finance, Money, Fundamental analysis, Profit, Corporate finance, Economy, Earnings before interest, taxes, depreciation and amortization, Private equity, Earnings guidance, New York Stock Exchange, CLF

Cleveland-Cliffs Inc. (NYSE: CLF) today provided updated financial guidance based on its most recent 2021 financial forecast.

Key Points: 
  • Cleveland-Cliffs Inc. (NYSE: CLF) today provided updated financial guidance based on its most recent 2021 financial forecast.
  • The Company will announce its full second-quarter 2021 earnings results before the U.S. market open on Thursday, July 22, 2021.
  • The call can be accessed at www.clevelandcliffs.com and will also be archived and available for replay at that address.
  • * Adjusted EBITDA is a non-GAAP financial measure that management uses in evaluating operating performance.

ScottsMiracle-Gro Increases Fiscal 2021 Guidance Led by Continued Strength in Both U.S. Consumer and Hawthorne Segments

Retrieved on: 
Tuesday, June 1, 2021
Finance, Money, Companies, Corporate finance, Lawn care, Scotts Miracle-Gro Company, Union County, Ohio, Scotts LawnService, Miracle-Gro, fis, Earnings guidance, Marysville, Ohio

MARYSVILLE, Ohio, June 01, 2021 (GLOBE NEWSWIRE) -- TheScotts Miracle-Gro Company(NYSE: SMG), the worlds leading marketer of branded consumer lawn and garden as well as indoor and hydroponic growing products, today announced increased sales and earnings guidance for fiscal 2021 based on the continued strength of both its U.S. Consumer and Hawthorne segments.

Key Points: 
  • MARYSVILLE, Ohio, June 01, 2021 (GLOBE NEWSWIRE) -- TheScotts Miracle-Gro Company(NYSE: SMG), the worlds leading marketer of branded consumer lawn and garden as well as indoor and hydroponic growing products, today announced increased sales and earnings guidance for fiscal 2021 based on the continued strength of both its U.S. Consumer and Hawthorne segments.
  • For the fiscal year ending September 30, 2021, ScottsMiracle-Gro now expects company-wide sales growth of 17 to 19 percent.
  • As a result, adjusted non-GAAP earnings are expected to be in a range of $9.00 to $9.30 per share.
  • This compares to the previous guidance of $8.60 to $9.00 per share.

Abbott Issues Updated 2021 Outlook

Retrieved on: 
Tuesday, June 1, 2021
Corporate finance, Finance, Money, Fundamental analysis, Financial ratios, Financial economics, Earnings per share, Earnings guidance

Abbott made significant contributions to the global fight against COVID-19, including the development of 12 tests globally.

Key Points: 
  • Abbott made significant contributions to the global fight against COVID-19, including the development of 12 tests globally.
  • Abbott projects 2021 diluted earnings per share from continuing operations under GAAP of $2.75 to $2.95.
  • Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be $4.30 to $4.50 for full-year 2021.
  • Abbott projects second-quarter 2021 guidance for diluted earnings per share from continuing operations under GAAP of at least $0.39.

CAVU Resources, Inc. announces sale of $2.645M property to homebuilder JP Orleans, releases Q1 earnings, and reaffirms annual guidance

Retrieved on: 
Wednesday, May 26, 2021
Articles, Economy, Business, Corporate finance, Earnings guidance, Chief operating officer

In addition, the company released its Q1 earnings, and its CEO, Kevin Vincent Cox re-affirmed the companys annual guidance.

Key Points: 
  • In addition, the company released its Q1 earnings, and its CEO, Kevin Vincent Cox re-affirmed the companys annual guidance.
  • The company is reporting Q1 earnings of $0.1 million on Q1 revenue of $1.3 million.
  • While it took longer than expected, we are excited to announce the sale of Alexander Manor.
  • Russ Sinacori, President and COO
    I have reviewed our financials and have confidence in our annual reporting for 2020 and for Q1 2021.

ZipRecruiter Announces First Quarter 2021 Results and 2021 Guidance

Retrieved on: 
Monday, May 17, 2021
Technology, Internet, Professional services, Human resources, Finance, Money, Economy, Corporate finance, ZipRecruiter, Earnings guidance, Investor

b'ZipRecruiter\xc2\xae, a leading online employment marketplace, today announced financial results for the quarter ended March 31, 2021.

Key Points: 
  • b'ZipRecruiter\xc2\xae, a leading online employment marketplace, today announced financial results for the quarter ended March 31, 2021.
  • ZipRecruiter\xe2\x80\x99s complete first quarter financial results, financial guidance and management commentary can be found by accessing the Company\xe2\x80\x99s shareholder letter on the quarterly results page of the investor relations website at investors.ziprecruiter.com .\nIn April, ZipRecruiter filed a registration statement with the U.S. Securities and Exchange Commission for a direct listing of its common stock.
  • We are issuing guidance for the year that maps to the strong signs of recovery in the U.S. hiring market.
  • We are well-positioned to take advantage of this moment as we continue to actively connect people to their next great opportunity.

Acadia Pharmaceuticals Reports First Quarter 2021 Financial Results

Retrieved on: 
Wednesday, May 5, 2021
Biotechnology, Pharmaceutical, Health, Mental health, Corporate finance, Finance, Money, Financial economics, NASDAQ, Pharmaceutical industry, Employee stock option, Earnings guidance, VCE

b'Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the first quarter ended March 31, 2021.\n\xe2\x80\x9cNUPLAZID delivered strong year-over-year performance in the first quarter of 2021.

Key Points: 
  • b'Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the first quarter ended March 31, 2021.\n\xe2\x80\x9cNUPLAZID delivered strong year-over-year performance in the first quarter of 2021.
  • Previous guidance included additional investments associated with the potential DRP launch in 2021 and updated guidance reflects a reduction in these expenses.
  • Current SG&A guidance includes approximately $50 million of stock-based compensation expense.\nAcadia management will review its first quarter financial results and operations via conference call and webcast today at 5:00 p.m. Eastern Time.
  • Acadia discovered and developed this new chemical entity and holds worldwide rights to develop and commercialize NUPLAZID.\nTrofinetide is an investigational drug.